Have Any Questions?

0512-86861701

ABOUT
Your Current Position:Home >> About >> Management Team

Xueming Qian, Ph.D., Founder,Chairman & CEO
Dr. Qian has over eighteen years of industrial antibody discovery and development experience. Before starting MABSPACE, Dr. Qian was Senior VP and Head of R&D of Shenogen Pharma Group from 2010 and 2012; a Beijing-based biopharma company developing ER-a36 based anti-cancer therapies. From 1997 and 2010 Dr. Qian worked at Amgen as principal scientist and led multiple project teams to discover novel antibody therapeutics for the autoimmune diseases and metabolic disorders (bone and kidney). He is the leading inventor of multiple antibody patents.Dr. Qian graduated from Fudan University and completed his graduate studies at Columbia University and Albany Medical Center.  He is a member of Antibody Society, International Society of Nephrology and BayHelixa member of National Thousand Talents program.

 

Tao Wu, Ph.D., Vice President, Antibody Discovery & Engingeering
Dr. Wu has over fifteen years of extensive experience of developing antibody drug. Before joining Mabspace, Dr. Wu was the leader and associate director of biological drug discovery at Janssen Pharmaceutical R&D center of Johnson & Johnson, China, responsible for antibody drug discovery strategy, teamed up with Janssen Biotherapeutics global, Asian specific innovation center and Pharmaceutical Development & Manufacturing Sciences (PDMS) collaboratively. Prior to J&J, Dr. Wu was the associate director of therapeutic antibody discovery at GlaxoSmithKline R&D Center in China. From 2011 to 2016, Dr. Wu worked at Boehringer Ingelheim Pharmaceuticals, USA as team leader and principal scientist, established high through put and high content hybridoma and B cell cloning platform, led antibody screening group and cross functional assay optimization team to discover high quality antibody therapeutics covering multiple therapeutic area. Prior to Boehringer Ingelheim, Dr. Wu worked at Pfizer and Merck for novel therapeutic antibody discovery. Dr. Wu graduated from The University of Hong Kong with Ph.D., Wuhan University with M.D., and authored one patent, one book chapter and twelve papers in peer-reviewed leading journals.

 

Li Zhen, Executive Director, Preclinical Development 
Mr. Li is currently responsible for the preclinical development of antibody based therapeutics at MabSpace. Mr. Li joined MabSpace in 2013 with more than 10 years industry experience of drug discovery and preclinical development. Before joining MabSpace, he was preclinical development project leaders in Shenogen Pharma, Hutchison Biopharma and Luye Pharma. He was involved in the preclinical study of various novel drugs, including Icaritin and ER-a36 targeting antibody, EGFR/c-Met /RON small molecular TKIs, sustained release microsphere projects at Luye.

 
Junjie Lisa Zheng, Senior Director,Process Development
Lisa has over 20 years working experience at Genentech where she mainly focused on cell line development, Phase I/III process development and tech transfer for many therapeutic antibody projects. She also supported CMC activities, IND filing, GMP manufacture campaigns, and BLA filing. She is an author for a book chapter publication and fourteen peer-reviewed journal publications. 
Guangliang Greg Pan, Ph.D., Senior Vice President, Head of CMC
He is currently the Vice President of MabSpace Biosciences heading CMC development. Dr. Pan has been involved in biologics drug product development and manufacturing for the past fourteen years. Dr. Pan accumulated extensive experience in biologics development and manufacturing during his employment with several internationally renowned biopharmaceutical companies. Prior to MabSpace, he was a senior biologics outsourcing manager and technical leader at Gilead Sciences. He was a principal research scientist at Lilly before he joined Gilead Science in 2014. During his tenure with Eli Lilly (2007-2014), he was a technical leader leading early and late phase protein drug product development and manufacturing. Before joining Eli Lilly in 2007 he was a senior research scientist at Novartis. Before Novartis,he joined Imclone as a senior scientist in 2004 and later promoted to manager and senior manager in monoclonal antibody formulation and analytical development. Dr. Pan graduated from Shandong University with BS degree in Bioengineering. He received his Ph.D. in pharmaceutics from the University of Georgia and completed his postdoctoral research in peptide transdermal delivery at Johnson and Johnson. He is a member of American Association of Pharmaceutical Sciences (AAPS), Parenteral Drug Association (PDA).
Yuntao Wan, Vice President, Clinical Development & Operations 

Currently serving as Vice President, Head of Clinical Development and Operations for MabSpace Biosciences in SuZhou,China. Yuntao has 20 years of experience in pharmaceutical and biotechnology, including 12 years in clinical development and operations and 8 years in discovery research.  Before joining MabSpace in May 2017, Yuntao was the Head of Clinical Sciences for Greater China at Bayer Healthcare in Beijing, responsible for China/Asia early phase development strategies of multiple therapeutic areas, including Oncology/Hematology, Cardiovascular/Anti-Thrombosis, Women’s health etc. Prior to Bayer, Yuntao spent close to 4 years with Roche, first at Roche Innovation Center Shanghai as the Head of Clinical Operations, and then as a Clinical Programs Leader at Roche Innovation Center New York. Yuntao also served as Senior Manager of trial management at Celgene Corp in New Jersey, USA, leading early phase clinical trials for 4 years in the areas of oncology and immunology, following 10 years at the legacy Schering-Plough Corp (now part of MSD) in various roles in discovery and clinical research. Yuntao completed a PhD education in Neurosciences (without dissertation), received Master of Science degree from Rutgers University of New Jersey, and a Bachelor degree in Biophysics from the Fudan University.

Copyright © 2017 Mabspace Biosciences All rights reserved